Larazotide acetate
Based on 4 publication(s) in Google Scholar
Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.24%
- CAS. Nr.: 881851-50-9
- Formel: C34H59N9O12
- Molecular Weight:785.89
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Antiviral Compound Library
HY-L027
-
Cytoskeleton Compound Library
HY-L060
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Peptide Library
HY-L105
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Larazotide acetate
More
Biologische Aktivität
Paracellular permeability[1]
Larazotide acetate (1-100 μM; 5 d) affects Vero cell growth[1]. Larazotide acetate (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively[1]. Larazotide acetate (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells[2]. Larazotide acetate (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Vero cell line
-
Concentration:1-100 μM
-
Incubation Time:5 days
-
Result:Inhibited Vero cell growth with an CC50 value of 82.5 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HLA-HCD4/DQ8 double transgenic mice[2]
-
Dosage:250 μg
-
Administration:Intraperitoneal injection; 250 μg twice a week for 7 weeks
-
Result:Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.
Chemical Information
-
CAS. Nr. 881851-50-9
-
Appearance Solid
-
Molecular Weight 785.89
-
Formel C34H59N9O12
-
Color White to off-white
-
Sequence
Gly-Gly-Val-Leu-Val-Gln-Pro-Gly
-
Sequence Shortening
GGVLVQPG
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. [Abstract]2020 Jun 19;11(1):3151. PMID: 32561730 -
EBioMedicine
Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation-induced enteropathy. [Abstract]2021 Nov:73:103641. PMID: 34688032 -
J Dent Res
2023 Jan;102(1):82-92. PMID: 36112881 -
JID Innov
The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis. [Abstract]2025 Apr 3;5(4):100369. PMID: 40330848
Lösungsmittel & Löslichkeit
H2O : 50 mg/mL (63.62 mM; Need ultrasonic)
DMSO : 2 mg/mL (2.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (127.24 mM); Clear solution; Need ultrasonic
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22(17):9427. [Content Brief]
[2]. Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.2724 mL | 6.3622 mL | 12.7244 mL | 31.8111 mL |
| H2O | 5 mM | 0.2545 mL | 1.2724 mL | 2.5449 mL | 6.3622 mL |
| 10 mM | 0.1272 mL | 0.6362 mL | 1.2724 mL | 3.1811 mL | |
| 15 mM | 0.0848 mL | 0.4241 mL | 0.8483 mL | 2.1207 mL | |
| 20 mM | 0.0636 mL | 0.3181 mL | 0.6362 mL | 1.5906 mL | |
| 25 mM | 0.0509 mL | 0.2545 mL | 0.5090 mL | 1.2724 mL | |
| 30 mM | 0.0424 mL | 0.2121 mL | 0.4241 mL | 1.0604 mL | |
| 40 mM | 0.0318 mL | 0.1591 mL | 0.3181 mL | 0.7953 mL | |
| 50 mM | 0.0254 mL | 0.1272 mL | 0.2545 mL | 0.6362 mL | |
| 60 mM | 0.0212 mL | 0.1060 mL | 0.2121 mL | 0.5302 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Larazotide acetate Related Classifications
HY-106268A Related Classifications
Powered by Bioz